Trial reportCancer immunology, immunotherapy : CII2025
Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study.
Trial report in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Case Report: Fecal microbiota transplantation resensitizes advanced non-small cell lung cancer to platinum-based chemotherapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to observe and compare the efficacy and safety of different anticoagulants combined with immunotherapy and chemotherapy for advanced nonsmall cell lung cancer (NSCLC).
methodsIn this prospective, randomized, controlled clinical trial, treatment-naïve subjects with stage
resultsIn this study, 143 patients were enrolled, including 46 in the control group, 48 in the LMWH group, and 49 in the rivaroxaban group. The median PFS of the control, LMWH, and rivaroxaban groups was 8.5 months (95%CI: 7.6-9.4), 8.6 months (95% CI: 8.1-9.1), and 11.2 months (95% CI: 9.4-13.0), respectively. Kaplan-Meier curve analysis showed no significant difference in PFS between the LMWH and control groups (HR = 1.041, 95% CI: 0.676-1.604; P = 0.852). The rivaroxaban group had significantly higher PFS than the control (HR = 0.766, 95% CI: 0.623-0.967; P = 0.021) and LMWH groups (HR = 0.582, 95% CI: 0.376-0.901; P = 0.013). No significant differences were observed in the ORR, complete response, partial response, DCR, or stable disease among the three groups (all P > 0.05).
conclusionsRivaroxaban combined with immune checkpoint inhibitors and chemotherapy has potential advantages in NSCLC treatment. It may enhance the antitumor efficacy by regulating immune functions, thereby prolonging the PFS of patients.
trial registrationTrial Registration: ChiCTR2500106653.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.